Enterprise Value
42.24M
Cash
4.846M
Avg Qtr Burn
-12.99M
Short % of Float
5.28%
Insider Ownership
16.69%
Institutional Own.
15.69%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s | PDUFA Approval decision | |
Olafertinib (CK-101) (EGFR Inhibitor) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 3 Update | |
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Failed Discontinued |